

Universal Biosensors Ltd

Q1 CY2012 Revenue and Cash Flow boosted by US Launch

The Revenue and Net Cash Flow for Q1 CY2012 improved substantially, with:

- A 79.6% increase in Revenue to \$6.4m and a \$1.3m increase in Operating Profit from zero to \$1.3m.
- A reduction in the Cash Outflow from (\$3.1m) to breakeven, through:
 - A 14.2% increase of Receipts to \$6.6m, 94% above Q4 CY2011. Excluding milestones, payments, this was the highest quarterly Receipts.
 - An 18.4% fall in Payments to -\$6.7m and 6.1% below Q4 CY2011. This was despite additional payments of around \$0.6m.
- Cash at 31/3/12 increased by \$0.6m to \$15.7m.

The improvement was due to:

- The launch of the OneTouch Verio IQ meter in the USA in January 2012 and Canada in late CY2011, resulting in increased product sales and service fees.
- Receipt of payments for the LifeScan development project of over \$1.1m.
- Control of the cost base.

The positive trend was confirmed by strong Q1 CY2011 growth and a further recovery in market share for LifeScan, partly attributed to the Verio launch. LifeScan achieved the highest quarterly sales since the Q3 CY2008 and eclipsed Roche, the global leader in blood glucose.

Blood Glucose underpins a move to profitability

The increasing profitability of the Blood Glucose sector of UBI's business and milestone payments on a second product will outweigh corporate costs and ongoing R&D costs on new products during the 2H CY2012.

Accordingly, UBI will be cash flow positive and profitable in CY2013, through:

- Increasing sales of strips to LifeScan and service fees with the continued rollout of the OneTouch Verio IQ meter in North America, the relaunch into Europe and the introduction into new markets.
- Continued cash flow from LifeScan development programs.
- Milestone payments with the development of blood coagulation products for Siemens and the supply of strips for the launch of the first product in CY2013.

Reasons to BUY

Growth Markets – Exposure to large rapid growth Point-of-Care Healthcare sectors, estimated at US\$15b and forecast to grow at around 11% pa, with a strong position in the escalating blood glucose market and the imminent launch of its Blood Coagulation meter system through Siemens.

Industry Position – Leading edge technology, a strong IP position, backed by a strong R&D team, strong partnerships and successful management and Board.

Development Pipeline – A strong pipeline, with a further 3 projects under development.

Improving Financial Position – UBI is expected to be Cash Flow positive and profitable in CY2013, supported by a strong Balance Sheet, with Cash of \$15.7m.

Valuation – Currently trading at a 58% discount to our valuation of \$1.81 ps.

UBI.ASX

BUY

4 May 2012

Price	\$0.75
Price Target	\$1.81
Valuation method	DCF
GICS sector	Healthcare
12 Mth Price Range	\$0.63 - 1.39
Avg monthly t/o	1.7m
Market Capitalisation	\$119m
Shares on issue	159m
Enterprise value	\$96m
Previous rating	BUY

	Year Ended Dec 30	10A	11A	12E	13E	14E
Revenue	\$m	18	14.7	30.3	51.8	79.0
EBITDA	\$m	-4.8	-12.1	-0.9	7.4	20.4
EBITDA margin	%	32.4	11.4	44.1	42.9	47.9
EBIT	\$m	-7.8	-15.4	-4.6	3.4	16.2
EBIT margin	%	-42.9	-104.8	-15.3	6.6	20.5
NPAT	\$m	-6.6	-14.7	-4.3	3.6	16.5
EPS	¢ ps	-4.2	-9.2	-2.7	2.3	10.4
DPS	¢ ps	0.0	0.0	0.0	1.0	4.0
Franking	%	0.0	0.0	0.0	0.0	0.0
PER	x	na	na	na	32.9	7.2
Dividend yield	%	0.0	0.0	0.0	1.3	5.3
NTA/share	¢ ps	29.7	22.0	19.3	21.6	30.5
EV/EBITDA	x	-19.9	-8.6	na	13.4	4.2
Gearing (D:E)	%	0.0	0.0	0.0	0.0	0.0
P/OCF	x	-37.3	-16.7	na	21.6	6.7
ROA	%	-14.2	-31.1	-9.9	6.8	26.4
ROE	%	-13.4	-35.7	-13.2	11.2	39.9
Interest cover	x	na	na	na	na	na

UBI v XSI (S&P/ASX Small Industrial Index)



Activities

Development & commercialisation of medical diagnostic devices, especially for point of care in vitro tests.

www.universalbiosensors.com


Brent Mitchell 03 86054830

bmitchell@veritassecurities.com.au

Q1 CY2012 Profit & Loss

For Q1 CY2012, UBI reported a \$1.3m recovery in Operating Profit from zero to \$1.3m and a 21.2% reduction in Net losses to (\$2.4m), on a 79.6% increase in revenue to \$6.4m.

While UBI reported a loss, the result does confirm that the Blood Glucose sector of UBI is increasingly profitable, with a Q1 CY2012 EBIT of \$1.3m, which follows EBIT of \$1.7m for Q4 CY2011 and \$1.7m for CY2011. At the corporate level, this profit and positive Cash Flow is being offset by R&D on new systems and Corporate costs, as follows:



	CY2011				CY2012	
	Q1	Q2	Q3	Q4	Q1	Ch %
Blood Glucose	\$m	\$m	\$m	\$m	\$m	%
Revenue from Products	3.3	2.3	2.2	4.3	4.7	42.3
Revenue from Services	0.2	0.5	0.3	1.6	1.7	582.1
Total Revenue - Blood Glucose	3.6	2.7	2.5	5.9	6.4	79.6
Cost of Goods Sold	-3.6	-2.8	-2.4	-4.3	-5.1	43.3
Operating Profit - Blood Glucose	0.0	-0.1	0.1	1.7	1.3	
less						
R&D	-1.7	-3.0	-2.3	-2.8	-2.3	29.6
Corporate Costs	-1.4	-1.8	-2.0	-2.0	-1.5	5.7
EBIT- UBI	-3.1	-4.9	-4.2	-3.2	-2.4	-22.3
Interest & Other Expenses	0.1	0.0	0.9	-0.2	0.0	
Net Loss	-3.1	-4.9	-4.2	-3.2	-2.4	-22.3

Product sales increase by 42.3% with the US launch of Verio

Service revenue boosted by project and royalty revenue

Revenue - The increase in Revenue was due to:

- An increase in product sales of 42.3%, with the launch of the OneTouch Verio IQ meter by LifeScan in the USA in January 2012 and Canada in November 2011. With the higher volume, UBI was paid on the ongoing basis of standard cost plus a margin.
- A 582% increase in Service revenue from :
 - An increase in royalty received on strips sold by Lifescan, with a 116% increase over Q4 CY2011.
 - Payments under the LifeScan development project of around \$1.1m.

Operating Profit - A \$1.3m increase in Operating Profit from zero to \$1.3m, comprising:

- A loss of \$0.1m from the production of strips. This is below the \$0.5m profit in Q4 CY2011, due to additional costs in ramping-up production, in terms of increase labour and training costs and increased wastage. This is expected to correct in Q2 CY2012.
- A Profit on Services of \$1.5m.

EBIT – 22.3% fall in Losses to (\$2.4m), with:

- **R&D** – a 29.6% increase in R&D, related to the finalisation of development on the PT/INR meter system for Siemens and ongoing R&D on additional testing systems for Siemens and immunoassay.
- **Corporate Costs** – Costs increased by 5.7%, although significantly lower than Q3 and Q4 CY2011, due to lower business development costs, mainly related to the Siemens agreement.

Cash Flow - The Net Cash Flow for Q1 CY2012 improved substantially, from an Outflow of -\$3.1m in Q1 CY2011 and -\$3.6m in Q4 CY2011 to breakeven in Q1 CY2012.

- A 14.2% increase of Receipts for Q1 over pcp to \$6.6m (94% v Q4 CY2011), the highest quarterly receipts, excluding the milestone payment of \$17.7m in Q4 CY2009.
- A 18.1% fall in Payments for Q1 over the pcp to -\$6.7m (-6.1% v Q4 CY2011), despite additional payments of around \$0.6m, with pre-payment of its annual insurance.

Operating Cash Outflow reduced from \$3.1m to breakeven

Retains \$15.7m in cash

Balance Sheet - Cash at 31/3/12 increased by \$0.6m to \$15.7m, excluding around \$0.6m of short term debt, related to the prepayment of insurance.

Outlook

LifeScan - UBI have foreshadowed a continuing increase in Revenue through CY2012 and beyond, from:

US sales to escalate

- Additional product sales to LifeScan with an increasing take up of OneTouch Verio IQ in the US, the relaunch by LifeScan of the upgraded Verio IQ meter in Europe accompanied by increased marketing and the launch in other LifeScan markets.
- Increasing services revenue from:
 - Increasing strip sales by LifeScan with a ramp-up of production also at its Inverness plant.
 - A further contribution from the LifeScan Development project in CY2012 of over \$2.0m. Once completed, we would expect further projects, although timing is uncertain

Verio strategic for LifeScan in building market share

The Verio is important in LifeScan strategy of regaining recently lost market share, with evidence in Q1 CY2012 of a positive impact on LifeScan's sales and a further recovery in market share. LifeScan reported growth in US Q1 CY2012 sales of 13.2%, with global sales exceeding Roche, the global leader in blood glucose (See Page 5).


Siemens to launch PT/INR in CY2013

Margins on product sales are expected to improve in Q2 onwards, towards 20%.

Siemens - UBI continues to expect Siemens to launch the PT/INR system in CY2013, in Europe and/or the USA. Meanwhile, UBI will receive Milestone payments from Siemens for the PT/INR meter system and the development of additional blood coagulation testing systems.

Immunoassay – With further development of D-dimer and Proof of Concept in CY2012, there is potential for milestone payments with the securing of sales and distribution partners and further development of the testing systems.

Molecular Diagnostics - This market was one of the potential markets identified by UBI after blood coagulation and development of an immunoassay platform, as a major global market. The molecular diagnostic market is valued by Global Data in Nov 2009 at more than US\$3.5b and is expected to grow at a CAGR of 14% to US\$6.2b by 2015.



Forecasts

This improved result for UBI was expected and does not materially affect revenue forecasts, which are based on:

- Escalating growth in revenue for the Diabetes division with an increasing take up of Verio in the US, the relaunch in Europe and the launch in other LifeScan markets.
- An increased contribution in CY2012 from the LifeScan development project.
- Milestone payments from Siemens and the approval in CY2012 of PT/INR testing systems for release in the US and/or Europe in CY2013.

Some increase in R&D costs over the balance of CY2012, but stable in CY2013. The main determinants of R&D will be:

- The development program for Siemens of subsequent meters to the PT/INR meter system.
- Proof of Concept in immunology for the D-dimer and CRP meter systems.
- Continued development in molecular diagnostics.



Universal Biosensors (UBI)

Current Price: \$0.75 ps Price Target: \$1.81 ps

Universal Biosensors

FINANCIAL PERFORMANCE

Year ended 31-Dec	2010A	2011A	2012E	2013E	2014E	2015E
Sales Revenue	\$m 18.2	14.7	30.3	51.8	79.0	105.1
Cost of Goods Sold	\$m -12.3	-13.0	-17.0	-29.5	-41.2	-51.0
Gross Operating Profit	\$m 5.9	1.7	13.4	22.2	37.8	54.1
R&D	\$m -6.5	-9.8	-9.0	-8.5	-8.5	-8.5
Administration Costs	\$m -4.2	-4.0	-5.5	-6.3	-5.5	-6.0
Other	\$m 0.0	0.0	0.2	0.0	-3.4	-4.1
EBITDA	\$m -4.8	-12.1	-0.9	7.4	20.4	35.5
Depreciation	\$m -3.0	-3.3	-3.7	-4.0	-4.2	-4.4
EBIT	\$m -7.8	-15.4	-4.6	3.4	16.2	31.1
Interest	\$m 1.2	0.7	0.3	0.2	0.3	1.3
Pre Tax Profit	\$m -6.6	-14.7	-4.3	3.6	16.5	32.4
Tax	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Reported Profit	\$m -6.6	-14.7	-4.3	3.6	16.5	32.4

GROWTH	2010A	2011A	2012E	2013E	2014E	2015E
Revenue	% 320.8	-19.2	106.4	70.7	52.7	33.0
COGS	% 1857.7	6.0	30.3	74.1	39.5	23.8
Gross Operating Profit	% -72.5	-71.6	696.9	66.3	70.2	42.9
R&D	% -56.5	51.4	-8.3	-5.6	0.0	0.0
EBITDA	% na	151.6	-92.3	-898.3	175.0	73.5
EBIT	% na	97.4	-69.9	-174.1	373.2	91.3
Reported Profit	% na	122.3	-70.5	-183.8	355.4	95.9
EPS	% na	120.2	-70.5	-183.8	355.4	95.9

P&L RATIOS	2010A	2011A	2012E	2013E	2014E	2015E
Gross Operating Profit / Sales	% 32.4	11.4	44.1	42.9	47.9	51.5
EBITDA / Sales	% -26.5	-82.4	-3.1	14.4	25.9	33.7
EBIT / Sales	% -42.9	-104.8	-15.3	6.6	20.5	29.6
Effective Tax Rate	% 0.0	0.0	0.0	0.0	0.0	0.0
Interest Cover	x na	na	na	na	na	na

Per SHARE	2010A	2011A	2012E	2013E	2014E	2015E
Issued Shares (Wt Avg)	m 157.6	159.0	159.0	159.1	159.1	159.1
EPS	¢ps -4.2	-9.2	-2.7	2.3	10.4	20.4
Operating Cash Flow ps	cps -4.1	-4.5	2.1	3.5	11.2	21.3
Free Cash Flow	¢ps -5.5	-5.2	0.9	2.2	9.9	19.7
DPS	¢ps 0.0	0.0	0.0	1.0	4.0	8.0
Franking	% 0.0	0.0	0.0	0.0	0.0	0.0
Dividend Payout Ratio	% 0.0	0.0	0.0	43.8	38.5	39.3

PARAMETERS	2010A	2011A	2012E	2013E	2014E	2015E
PE Ratio	x -36.2	-8.1	-27.5	32.9	7.2	3.7
Enterprise Value / EBITDA	x -19.9	-8.6	-110.5	13.4	4.2	1.8
Enterprise Value / Profit	x -14.5	-7.1	-23.7	27.3	5.2	2.0
Cash Flow ratio	x -37.3	-16.7	35.5	21.6	6.7	3.5
Dividend Yield	% 0.0	0.0	0.0	1.3	5.3	10.7

SEGMENTS	2010A	2011A	2012E	2013E	2014E	2015E
Sales Revenue						
Product Sales	\$m 11.8	12.1	19.5	36.5	57.3	57.3
Service Revenue	\$m 6.4	2.6	7.4	12.2	19.2	19.2
Milestone Payments	\$m 0.0	0.0	3.5	3.0	2.5	2.5
EBIT						
Product Sales	\$m 1.0	-0.2	3.9	7.6	14.3	14.3
Service Revenue	\$m 4.9	1.9	5.5	10.3	17.0	17.0
R&D	\$m -6.5	-9.8	-9.0	-8.5	-8.5	-8.5
Milestone Payments	\$m 0.0	0.0	3.5	3.0	2.5	2.5
Corporate	\$m -7.2	-7.3	-8.5	-9.0	-9.0	-9.0
EBIT Growth						
Product Sales	% na	-125.7	-1677.2	95.4	87.8	87.8
Service Revenue	% 22.9	-61.0	184.6	88.5	64.2	64.2
R&D	% -56.5	51.4	-8.3	-5.6	0.0	0.0
EBIT Margin						
Product Sales	% 8.2	-2.0	20.0	20.8	24.9	24.9
Service Revenue	% 76.9	73.1	74.2	84.5	88.3	88.3

CASH FLOW

Year ended 31-Dec	2010A	2011A	2012E	2013E	2014E	2015E
Operating EBITDA	\$m -4.8	-12.1	-0.9	7.4	20.4	35.5
Net Interest Received/Paid	\$m 1.2	0.7	0.3	0.2	0.3	1.3
Tax Paid	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Change Working Capital	\$m -4.7	-2.9	4.0	-2.1	-3.0	-3.0
Other	\$m 1.9	7.1	0.0	0.0	0.0	0.0
Operating Cash Flow	\$m -6.4	-7.2	3.4	5.5	17.7	33.8
Capex	\$m -2.3	-1.1	-2.0	-2.0	-2.0	-2.5
Free Cash Flow	\$m -8.7	-8.3	1.4	3.5	15.7	31.3
Acquisitions/Asset Sales	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Dividends Paid	\$m 0.0	0.0	0.0	0.0	-2.4	-9.5
Equity Change	\$m 0.7	0.1	0.0	0.0	0.0	0.0
Debt Change	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Change in Net Cash	\$m -8.0	-8.2	1.4	3.5	13.4	21.8

BALANCE SHEET

	2010A	2011A	2012E	2013E	2014E	2015E
Cash	\$m 23.3	15.1	16.4	20.0	33.3	55.1
Receivables	\$m 3.6	4.9	6.0	8.0	10.0	13.3
Inventory	\$m 3.2	3.6	6.0	7.5	11.0	14.6
Other Current Assets	\$m 0.3	1.0	0.9	1.0	1.0	1.0
Current Assets	\$m 30.4	24.6	29.3	36.5	55.3	84.0
Property, Plant & Equipment	\$m 23.1	20.3	18.6	16.6	14.4	12.5
Intangibles	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Other NC Assets	\$m 0.3	0.3	0.0	0.0	0.0	0.0
Non Current Assets	\$m 23.4	20.6	18.6	16.6	14.4	12.5
Total Assets	\$m 53.8	45.2	47.9	53.1	69.7	96.5
Payables	\$m 1.8	0.6	8.1	9.5	12.0	16.0
Current Debt	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	\$m 2.7	6.4	4.5	6.0	6.5	7.0
Current Liabilities	\$m 4.5	7.0	12.6	15.5	18.5	23.0
Non Current Debt	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Other NC Liabilities	\$m 2.2	3.2	4.7	3.3	2.8	2.3
Non Current Liabilities	\$m 2.2	3.2	4.7	3.3	2.8	2.3
Total Liabilities	\$m 6.6	10.2	17.3	18.8	21.3	25.2
Shareholder Funds	\$m 47.2	35.0	30.7	34.3	48.5	71.3

BALANCE SHEET RATIOS

	2010A	2011A	2012E	2013E	2014E	2015E
Receivables turn	x 9.1	3.5	5.6	7.4	8.8	9.0
Inventory turn	x 7.0	3.8	3.5	4.4	4.5	4.0
Net Debt	\$m 0.0	0.0	0.0	0.0	0.0	0.0
Gearing (D:D+E)	% 0.0	0.0	0.0	0.0	0.0	0.0
Current Ratio (CA / CL)	x 6.8	3.5	2.3	2.4	3.0	3.7
Net Assets	¢ps 29.7	22.0	19.3	21.6	30.5	44.7
Net Tangible Assets	¢ps 29.7	22.0	19.3	21.6	30.5	44.7
Cash	¢ps 14.7	9.5	10.3	12.6	21.0	34.6
Price to Book Value	x 2.5	3.4	3.9	3.5	2.5	1.7
Return On Assets	% -14.2	-31.1	-9.9	6.8	26.4	37.4
Return on Equity	% -13.4	-35.7	-13.2	11.2	39.9	54.1

VALUATION

Valuation Method	\$ ps	Premium/(Discount) to Current price
DCF	1.81	58.6%
Current Price	0.75	
Market Capitalisation	\$119.3m	Enterprise Value
		\$102.8m

MAJOR SHAREHOLDERS

Principals C'stone/Directors	m 14%
CM Capital Investments	m 11%
Johnson & Johnson	m 9%
PFM Cornerstone	m 7%
Top 20 (16/3/2011)	m 74%

DIRECTORS

Andrew Denver	N-E Chair	Andrew Jane	N-E Dir
Paul Wright	MD & CEO	Dr Jane Wilson	N-E Dir
Dr Colin Adam	N-E Dir	Marshall Heinberg	N-E Dir
Denis Hanley	N-E Dir		


Source: UBI (Act) and Veritas Securities (Est)

Johnson & Johnson (LifeScan) Q1 CY2012 Revenue Result

The Q1 CY2012 Report for Johnson & Johnson Diabetes Care (over 90% LifeScan, 10% insulin delivery), confirmed a strong upward trend in sales (particularly the US) and a further recovery in market share with operational sales growth of 6.6%, comprising US growth of 13.2% and International growth of 0.2%.

This contrasts with Roche Diabetes (the market leader), who reported a substantial revenue decline in both Q4 CY2011 and Q1 Cy2012. LifeScan's global market share exceeded Roche for the 1st time in many years.

J&J Diabetes	Revenue	Operational Growth v		Roche	Revenue	Operational Growth v	
	Q1 CY2012	Q1 CY2011	Q4 CY2011		Q1 CY2012	Q1 CY2011	Q4 CY2011
	US\$m	%	%		US\$m	%	%
US	352	13.2	6.7	US	129	-5.0	-32.0
International	318	0.2	-6.5	International	482	-8.0	-20.0
Total	670	6.6	0.2	Total	611	-7.0	-24.0



Source: John & Johnson – Quarterly releases

US - J&J management have attributed the US revenue growth in part to launches of new products, most notably the pattern-recognising LifeScan Verio IQ, which is now in the process of global launch.

However, it's important to note:

- This is J&J's highest quarter of US revenue since the Q3 CY2008 (US\$349m) which was part of a build-up in sales related to a release of the previous model. Q1 CY2012 was the 1st time in 5 years that sequential Q4 to Q1 growth has been positive, and followed a Q4 CY2011 increase of 4.1% (US +3.8%), and a CY2011 increase of 5.0% (US +4.2%).
- The underlying growth would have been higher, except for a recall of the new US meters announced on 23/2/12.

While there has been little underlying growth for LifeScan since Q3 CY2008, despite significant overall market growth (suggesting a loss of market share), US sales have been trending upwards and market share recovering. Accordingly, the successful launch and rollout of Verio is an important part of the J&J strategy to recover any lost share and grow market share in the US (the largest global market) and elsewhere.

International - The modest increase of 0.2% was a balance of continued strong growth in developing markets, offset by a decline in developed markets (particularly Europe), with price pressures and changes in re-imbursements. The international trends are less discernible, due to currency considerations.

Q1 sales exceed Roche, the global leader

This result for Johnson & Johnson Diabetes is in contrast to Roche Diabetes (the market leader), who reported a substantial revenue decline in both Q4 CY2011 and Q1 CY2012. LifeScan's global market share exceeded Roche for the 1st time in many years.

However, a significant part of the decline for Roche is attributable to:

- The launch by LifeScan of the Verio in North America and the destocking ahead of an expected launch by Roche in Q2 CY2012 of the recently approved Accu-Chek Nano SmartView meter in the US.
- In EMEA, the fall was due to pricing pressure and re-imbursement issues. For instance, re-imbursements in Poland were removed for two months. Roche also experienced some deferment ahead of the release on a its Accu-Chek Mobile in Q2 CY2012

Sales

Robert Scappatura +61 2 8252 3240
 Tony Bonello +61 2 8252 3230
 Andrew McCauley +61 2 8252 3260
 Patrick Ford +61 2 8252 3211
 Sam Streeter +61 2 8252 3235
 Willem Ter Avest +61 2 8252 3270
 Clay Melbourn +61 2 8252 3220
 Bryce Reynolds +61 2 8252 3215
 Stephen Murphy +61 8 9380 8351

Research

Industrials
 Brent Mitchell +61 3 8605 4830
 Levi Hawker +61 3 8676 0689

Resources
 Piers Reynolds +61 3 8601 1196
 Matt Baillie +61 2 8252 3275

RATING

BUY – anticipated stock return is greater than 10%
 SELL – anticipated stock return is less than -10%
 HOLD – anticipated stock return is between -10% and +10%
 SPECULATIVE – High risk with stock price likely to fluctuate by 50% or more

This report has been issued by Veritas Securities Limited A.B.N. 94 117 124 535, Australian Financial Services Licence Number 297043.

Disclaimer. The information contained in this document is general information only and is not financial or investment advice, and does not take into account your specific financial situation, particular needs and investment objectives. This document has been prepared from sources which Veritas Securities Limited ("Veritas") believes to be reliable, but none of Veritas, its directors, employees and associates ("Veritas Parties") give or make any representation or warranty that any such information is accurate, complete, reliable or up-to-date, and Veritas disclaims all liability for loss or damage, direct or indirect, suffered by any person arising from any use of or reliance on such information. Veritas recommends that you consult your financial adviser before making any financial or investment decision. Veritas does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document.

Disclosure of interest. Veritas Parties may receive or may have received fees, commissions and brokerage by acting as corporate adviser or broker for companies described in this document, and may hold directorships or other offices with such companies. Veritas Parties may hold an interest in securities or financial products described in this document, may benefit from an increase in the price or value of them, and may effect or participate in transactions which are inconsistent with any statement made in this document.

Veritas Securities Limited	Sydney	Melbourne	Perth
A.B.N. 94 117 124 535	Level 4, 175 Macquarie Street	Level 8, 350 Collins Street	Suite 5, 531 Hay Street
AFSL No. 297 043	Sydney, NSW, 2000	Melbourne, VIC, 3000	Subiaco, WA, 6008
GPO Box 4877, Sydney, NSW, 2001	Tel: (02) 8252 3200	Tel: (03) 8601 1196	Tel: (08) 9380 8351
www.veritassecurities.com.au	Fax: (02) 8252 3299	Fax: (03) 8601 1180	Fax: (08) 9380 8300